Clinical Research Centre Overview

Clinical trials and research studies are a key component of the evidence-based research approach of Beacon Hospital’s Clinical Research Centre.

Clinical trials test new treatments in people with cancer, such as new drugs, new treatment combinations, new approaches (surgery or radiation therapy) or new methods (gene therapy). The goal of this research is to find better ways to treat cancer and help cancer patients.

If a new treatment proves effective in a study, it may become a new standard treatment that can help many patients. Most of today’s most effective standard treatments are based on previous study results, such as those for breast, colon, rectal, and childhood cancers.

Individuals who participate may be helped personally by the treatment(s) they receive. Trial participants get up-to-date care from cancer experts, and they receive either a new treatment being tested or the best available standard treatment for their cancer.

While there are no guarantees that a new treatment being tested will not carry risks or produce good results, if a new treatment proves effective, or more effective than the standard treatment, participants in the clinical trial may be among the first to benefit.

While research studies are of importance in therapeutic advancement, Beacon Hospital’s Clinical Research Centre prioritises the rights, safety, and well-being of patients involved in clinical trials. Apart from the fact that all our clinical studies have secured approval from the Medical and Research Ethics Committee of the Ministry of Health, Malaysia, we also comply with local and international Good Clinical Practice (GCP) standards to safeguard the ethical interests of trial patients.

To date, our oncology team has participated in numerous clinical trials including in comparing the effectiveness of different chemotherapy treatments; resistance to inhibitors; epigenetic changes in nasopharyngeal cancer; and treatment for advanced or metastatic gastroesophageal junction adenocarcinoma, among others.

No.Clinical TrialStatus
A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine
Active (Recruiting)
2PFIZER A7471067
Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review
Active (Recruiting)
A Phase 2, Multi-Center, Randomised study to compare the efficacy and safety of MK-7684-A or MK-7684-A Plus Docetaxel versus Docetaxel Monotherapy in the treatment of particpants with Metastatic NSCLC with progressive disease after treatment with a Platinum Doublet Chemo or Immunotherapy
Active (Recruiting)
4MO42541- IMBRAVE251
A Phase III, Open-Label, Randomised Study of ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB Alone in Hepatocellular carcinoma previously treated with atezolizumab and bevacizumab
Active (Recruiting)
A phase 3, Open-Label, Randomised Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic NSCLC After Osimertinib Failure
Active (Recruiting)
6Pacific 8
A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy
Active (Recruiting)
7Adaura 2
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection
Active (Recruiting)
8InCyte Podium (INCMGA0012-304)
A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304)
Active (Recruiting)
A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Active (Recruiting)
10MS200095-0031-INSIGHT 2
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior Osimertinib therapy.
Active (Recruiting)
Study of JDQ443 in Comparison with Docetaxel in Participants with Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Active (Recruiting)
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
Active (Recruiting)
A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation
Active (Recruiting)
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
Active (Recruiting)
15Krystal 10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Active (Recruiting)
16Origami -1
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Active (Recruiting)
A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation
Active (Recruiting)
A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA).
Active (Recruiting)
19Invitrocue PDO for drug screening
Validating the use of patient-derived organoids for predicting drug response to chemotherapy in patients with advanced solid cancers
Active (Recruiting)
20CBYL719H12301 – EPIK B3
A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.
Active (Recruiting)
21ATORG 001
A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).
Active (Recruiting)
Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer
(Investigator Initiated Research)
Active (Recruiting)
23CT-P16 3.1
A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.
(Stop Recruiting)
A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).
(Stop Recruiting)
A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma
(Stop Recruiting)
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
(Stop Recruiting)
Bone turnover markers reference database in five
South East Asia Countries
A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5FU versus placebo in combination with cisplatin and 5FU as first-line treatment in subjects with advanced/metastatic esophageal carcinoma
Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor
30Tessa FF01:
A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC
31Hyperthermia – REMISSION 1C
Hyperthermia in Treating Patients with Unresectable Abdominal, Pelvic tumours and Cutaneous and Peritoneal Metastases
A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease
34Studies On Epigenetic Changes In Nasopharyngeal CancerCompleted
35Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer CareCompleted
36Healthcare Performance Measurement And Reporting For Breast Cancer Services In MalaysiaCompleted
(View Abstract)
(View Paper)
37A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction AdenocarcinomaCompleted
38A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.Completed
39An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC)Completed

Apart from oncology clinical trials, our consultants from other centres of excellence have also made substantial contributions to their clinical specialty with their published research. Below are the research publications (abstract, research papers, poster presentations, etc) produced by our consultants:


Publication Title

Name of Consultant

Type of Presentation


Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care


Healthcare Performance Measurement And Reporting For Breast Cancer Services in Malaysia


Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs

Dr Ong Chin Tuan
(Consultant Ophthalmologist)


Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis

Dato Ibrahim
Dr Azura
Arkonam Balasubramaniam Manivannan (Consultant Oncologists)
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)


Presenting complaints of patients and palliative care referral patterns

Dr Felicia Chang
Dr Azura
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)


Impact of a digital educational program on nurses’ knowledge and attitudes toward pain assessment and management in a Malaysian hospital.

Dr Koon Sim Lan
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

If you are interested and want to know more about these ongoing trials, please contact us at +603-7787 2854 or you can drop us an email at